semaglutide fda update Novo Nordisk has announced that the has approved the Wegovy® pill (once-daily oral 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults Following FDA nod, Novo Nordisk

What Each Receptor Does GLP-1 (Glucagon-Like Peptide-1) The foundation of all GLP-1 medications

123,124 Feeding table scraps has been associated with canine obesity, 124 a greater than 3-fold increased risk of canine diabetes, 125 and a 26-fold increased risk of pancreatitis (inflammation and self-destruction of the pancreas that can range in severity from mild to fatal)

For example, in one study, participants using semaglutide lost an average of 15% of their body weight over 68 weeks

Management of antiplatelets in an acute setting Key Concept: Platelets should be administered in the setting of severe LGIB to maintain a platelet count of .30 3 109 /L, and a higher threshold of .50 3 109 /L can be considered if endoscopic procedures are required